Furthermore, Weigelt et al. [28] state that during the acquisition of resistance to targeted therapies, breast cancer cells are able to rapidly adapt to different environments and signaling cues by switching between alternative pathways, specifically PI3K/AKT and RAS-MEK-ERK, that in turn regulate proliferation and cell survival. The gene discussed is MAP2K7; the disease is breast carcinoma.